MREO Stock Forecast & Price Target

Mereo BioPharma Group is positively positioned because the Sentynl option agreement externally validates alvelestat in AATD-LD while preserving Mereo’s ex-US rights, Phase 3 leadership, and potential economics of $40M upfront and R&D payments, up to $435M in milestones, and double-digit royalties. The alvelestat program also addresses a meaningful unmet need, supported by positive efficacy data in two Phase 2 trials and the possibility of a Phase 3 initiation in early 2027, which could add substantial long-term value. Setrusumab remains a key pipeline asset despite missed fracture endpoints, as FDA and MHRA discussions around alternative analyses continue, while $30.1M in cash and equivalents at 2Q26 is expected to fund operations into late 2027.

Mereo BioPharma Group is viewed negatively because its lead asset, setrusumab, failed to meet the pivotal fracture-reduction endpoints in both ORBIT and COSMIC, undermining the clearest regulatory and commercial path for a rare disease drug. While BMD and some pain-related measures improved, management has acknowledged BMD is not validated as a surrogate for fracture reduction in osteogenesis imperfecta, forcing reliance on post-hoc analyses, subgroup work, and OLE data expected in 4Q:26. The company also faces meaningful financing risk, since it will need additional funds to advance clinical programs and there is no assurance of favorable financing, milestone receipts, or new partnerships.